Adalimumab-adbm

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10540 publications

Cilioretinal-Sparing Central Retinal Artery Occlusion in a Child with Adenosine Deaminase 2 (ADA2) Deficiency.

Cilioretinal-Sparing Central Retinal Artery Occlusion in a Child with Adenosine Deaminase 2 (ADA2) Deficiency.

Journal: Ocular immunology and inflammation
Published: September 07, 2026

Switchback from biosimilar tumor necrosis factor-alpha inhibitors to reference medicines: a review.

Switchback from biosimilar tumor necrosis factor-alpha inhibitors to reference medicines: a review.

Journal: Expert review of clinical immunology
Published: September 03, 2026

Impact of Nonmedical Adalimumab Switches in a Rheumatology Patient Population.

Impact of Nonmedical Adalimumab Switches in a Rheumatology Patient Population.

Journal: The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians
Published: September 02, 2026

Long-term safety of steroid-sparing immunosuppression in uveitis.

Long-term safety of steroid-sparing immunosuppression in uveitis.

Journal: Current opinion in ophthalmology
Published: August 30, 2026

Adalimumab biosimilar uptake among dermatologists in Medicare Part D through 2023: A retrospective analysis using the Prescribers - by Provider and Drug dataset.

Adalimumab biosimilar uptake among dermatologists in Medicare Part D through 2023: A retrospective analysis using the Prescribers - by Provider and Drug dataset.

Journal: JAAD international
Published: August 28, 2026

Comparable long-term outcomes with biosimilar and originator adalimumab in juvenile idiopathic arthritis: a multicenter cohort study.

Comparable long-term outcomes with biosimilar and originator adalimumab in juvenile idiopathic arthritis: a multicenter cohort study.

Journal: Expert opinion on biological therapy
Published: August 26, 2026

Relentless Placoid Chorioretinitis in a Patient with Atopic Dermatitis Treated with Dupilumab.

Relentless Placoid Chorioretinitis in a Patient with Atopic Dermatitis Treated with Dupilumab.

Journal: Ocular immunology and inflammation
Published: August 25, 2026

Predictors of adalimumab durability in hidradenitis suppurativa: a multicenter cohort study.

Predictors of adalimumab durability in hidradenitis suppurativa: a multicenter cohort study.

Journal: The Journal of dermatological treatment
Published: August 20, 2026

Patient-Level Risk Characterization of Drug-Associated Hidradenitis Suppurativa Using Machine Learning.

Patient-Level Risk Characterization of Drug-Associated Hidradenitis Suppurativa Using Machine Learning.

Journal: medRxiv : the preprint server for health sciences
Published: August 20, 2026

Beyond the first switch: multiple switching, cross-switching, and nocebo-aware implementation of biosimilars in real-world care in non-US health systems.

Beyond the first switch: multiple switching, cross-switching, and nocebo-aware implementation of biosimilars in real-world care in non-US health systems.

Journal: Expert opinion on biological therapy
Published: August 13, 2026

Using Intralesional Adalimumab for Chronic Refractory Cutaneous Granulomatous Inflammation.

Using Intralesional Adalimumab for Chronic Refractory Cutaneous Granulomatous Inflammation.

Journal: Cutis
Published: August 13, 2026

Surgical Outcomes for Hidradenitis Suppurativa: Does Biologic Therapy Make a Difference?

Surgical Outcomes for Hidradenitis Suppurativa: Does Biologic Therapy Make a Difference?

Journal: Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
Published: August 12, 2026
Showing 1-12 of 10,540

Last Updated: 09/26/2026